Orexigen Therapeutics (OREX) : Traders are bullish on Orexigen Therapeutics (OREX) as it has outperformed the S&P 500 by a wide margin of 22.04% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 2.9%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.87% in the last 1 week, and is up 22.51% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Orexigen Therapeutics, Inc. is up 7.5% in the last 3-month period. Year-to-Date the stock performance stands at -75%. The stock has recorded a 20-day Moving Average of 14.06% and the 50-Day Moving Average is 4.56%.
Orexigen Therapeutics (NASDAQ:OREX): The stock opened at $4.38 on Friday but the bulls could not build on the opening and the stock topped out at $4.38 for the day. The stock traded down to $4.23 during the day, due to lack of any buying support eventually closed down at $4.30 with a loss of -1.60% for the day. The stock had closed at $4.37 on the previous day. The total traded volume was 67,151 shares.
Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company. The Company is focused on the development of pharmaceutical product candidates for the treatment of obesity. The Companys product is Contrave, a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER. The Companys product Contrave, is approved in the United States by the United States Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI), of around 30 kilograms per square meter (kg/m2) or greater (obese), or around 27 kilograms per square meter or greater (overweight) in the presence of at least one weight-related comorbid condition. The Company also submitted an application for marketing authorization with the European Medicines Agency (EMA) for Contrave under the name Mysimba.